Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Teriflunomide improves satisfaction versus prior DMT regardless of age

Teriflunomide improves satisfaction versus prior DMT regardless of age

Conference
MS Virtual 2020
Trial
Phase 4, Teri-PRO
In the phase 4, real-world Teri-PRO study, teriflunomide improved treatment satisfaction regardless of age in relapsing MS patients switching from other disease-modifying therapies (DMTs). Improvements occurred as early as week 4 and persisted at week 48 of treatment [1]. The presented subanalysis of Teri-PRO assessed changes in treatment satisfaction over 48 weeks in relapsing MS patients, stratified by age, who switched to teriflunomide 14 mg from prior DMTs. Four groups were identified: ≤35 years (n=85); >35 to ≤45 years (n=167); >45 to ≤55 years (n=175); and >55 years (n=129). Patients rated their satisfaction using the highly-validated Treatment Satisfaction Questionnaire for Medication (TSQM), version 1.4. Its 4 domains are: global satisfaction, effecti...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on